CD19-targeted CAR T cells in refractory antisynthetase syndromedoi:10.1016/S0140-6736(23)00023-5F. MüllerS. BoeltzJ. KnitzaM. AignerS. VlklS. KharboutliH. ReimannJ. TaubmannS. KretschmannW. RslerElsevier LtdThe Lancet
Taken together, these observations suggest that administration of immunoglobulin subcutaneously may be a useful therapeutic approach to tackle steroid-refractory antisynthetase syndrome while ensuring minimal side effects and improved treatment compliance. This treatment also allowed, in our case, for the reg...